A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; Inflammatory breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms BERENICE
- Sponsors Roche
- 24 Jul 2019 Planned End Date changed from 18 Aug 2020 to 26 Aug 2020.
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2018 Planned End Date changed from 3 Dec 2020 to 18 Aug 2020.